Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives $59.88 Consensus Target Price from Analysts

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) has been assigned a consensus recommendation of “Moderate Buy” from the seventeen research firms that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, thirteen have given a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $59.5625.

RARE has been the topic of several research analyst reports. Barclays reduced their price objective on shares of Ultragenyx Pharmaceutical from $44.00 to $43.00 and set an “overweight” rating on the stock in a report on Wednesday, April 29th. HC Wainwright reduced their price objective on shares of Ultragenyx Pharmaceutical from $60.00 to $50.00 and set a “buy” rating on the stock in a report on Tuesday, February 17th. The Goldman Sachs Group lowered shares of Ultragenyx Pharmaceutical from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $61.00 to $25.00 in a report on Tuesday, March 24th. Truist Financial upgraded shares of Ultragenyx Pharmaceutical to a “strong-buy” rating in a report on Wednesday, March 25th. Finally, Weiss Ratings upgraded shares of Ultragenyx Pharmaceutical from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 8th.

Insider Activity at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, EVP Eric Crombez sold 7,029 shares of the business’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $22.80, for a total transaction of $160,261.20. Following the sale, the executive vice president directly owned 76,301 shares in the company, valued at $1,739,662.80. This represents a 8.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Howard Horn sold 4,683 shares of the business’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $24.90, for a total transaction of $116,606.70. Following the sale, the chief financial officer owned 110,342 shares in the company, valued at $2,747,515.80. This trade represents a 4.07% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 117,262 shares of company stock valued at $2,687,403. 5.20% of the stock is owned by company insiders.

Institutional Trading of Ultragenyx Pharmaceutical

A number of institutional investors and hedge funds have recently bought and sold shares of RARE. Covestor Ltd lifted its holdings in Ultragenyx Pharmaceutical by 26.0% in the third quarter. Covestor Ltd now owns 1,787 shares of the biopharmaceutical company’s stock valued at $54,000 after acquiring an additional 369 shares during the period. Huntington National Bank lifted its holdings in Ultragenyx Pharmaceutical by 56.2% in the third quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 393 shares during the period. Xponance Inc. lifted its holdings in Ultragenyx Pharmaceutical by 3.1% in the third quarter. Xponance Inc. now owns 13,494 shares of the biopharmaceutical company’s stock valued at $406,000 after acquiring an additional 406 shares during the period. Amalgamated Bank lifted its holdings in Ultragenyx Pharmaceutical by 6.9% in the third quarter. Amalgamated Bank now owns 7,226 shares of the biopharmaceutical company’s stock valued at $217,000 after acquiring an additional 469 shares during the period. Finally, Arizona State Retirement System lifted its holdings in Ultragenyx Pharmaceutical by 2.2% in the third quarter. Arizona State Retirement System now owns 25,176 shares of the biopharmaceutical company’s stock valued at $757,000 after acquiring an additional 533 shares during the period. 97.67% of the stock is currently owned by hedge funds and other institutional investors.

Ultragenyx Pharmaceutical Trading Down 0.6%

Shares of RARE opened at $23.26 on Friday. The firm has a market cap of $2.29 billion, a P/E ratio of -3.81 and a beta of 0.39. Ultragenyx Pharmaceutical has a 12-month low of $18.29 and a 12-month high of $42.37. The company’s 50-day moving average price is $23.36 and its 200 day moving average price is $25.84.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported ($1.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.49) by ($0.35). The company had revenue of $136.00 million during the quarter, compared to analysts’ expectations of $158.19 million. Ultragenyx Pharmaceutical had a negative net margin of 91.03% and a negative return on equity of 1,024.42%. The firm’s quarterly revenue was down 2.2% on a year-over-year basis. During the same quarter last year, the firm posted ($1.57) earnings per share. Equities research analysts forecast that Ultragenyx Pharmaceutical will post -4.62 earnings per share for the current year.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.